Anhydrix™
Primary Focal Hyperhidrosis
Phase 2Licensed
Key Facts
About TheraVida
TheraVida is a private, clinical-stage biopharmaceutical company developing Anhydrix™, a proprietary oral combination drug for the treatment of hyperhidrosis. The company's core technology pairs an agonist with an antagonist in a unique formulation aimed at reducing side effects while maintaining efficacy. Following a successful Phase 2 trial, TheraVida has licensed Anhydrix™ to Dermavant Sciences for worldwide development, positioning the company as a pipeline-focused entity with a partnered asset.
View full company profile